期刊文献+

度洛西汀与舍曲林治疗伴有焦虑症状的抑郁症患者疗效比较 被引量:8

Comparison of efficacy of Duloxetine and Sertraline in treatment of depression with anxiety
下载PDF
导出
摘要 目的:探讨度洛西汀与舍曲林治疗伴有焦虑症状的抑郁症疗效和安全性。方法:78例符合入组标准的患者随机分成度洛西汀组和舍曲林组,各39例,治疗8周。患者于治疗前及治疗1、2、4、6、8周,应用汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)评定疗效,同时用治疗中出现的症状量表(TESS)评估安全性。结果:两组患者HAMD、HAMA总分均较治疗前显著下降(P<0.01);第1周度洛西汀组患者HAMD、HAMA总分下降显著比舍曲林组多(P<0.01),在其它几周差异无统计学意义(P均>0.05)。两组间不良反应发生率差异无统计学意义(P>0.05)。结论:度洛西汀与舍曲林治疗伴有焦虑症状的抑郁症疗效相当,但度洛西汀起效更快。 Objective:To evaluate efficacy and safety of Duloxetine and Sertraline in treatment of depression with anxiety.Methods:78 patients with depression with anxiety randomly received Duloxetine (n=39) and Sertraline (n=39) for 8 weeks. Beforeand 1, 2, 4, 6 and 8 weeks after the treatment, Hamilton depression scale(HAMD-17) and Hamilton anxiety scale (HAMA) wereused to evaluate the efficacy; the adverse events were assessed by the treatment emergent symptom scale (TESS) 1,2,4,6 and 8 weeksafter the treatment,respectively. Results: The HAMD-17 and HAMA total scores were improved significantly for both groups after thetreatment (P〈0. 01). At the end of the first week, the total scores of HAMD and HAMA in Duloxetine group were significant lowerthan those of the Sertraline group (P〈0. 01); while there were no statistical differences in the total scores of HAMD and HAMA be-tween the two groups 2, 4, 6 and 8 weeks after the treatment. The incidences of the adverse reactions between the two groups showed nosignificant difference(P〉0. 05). Conclusions: The efficacy on depression with anxiety is not different between Duloxetine and Sertra-line. However, Duloxetine has an earlier response than Sertraline.
出处 《中国民康医学》 2014年第17期8-9,共2页 Medical Journal of Chinese People’s Health
关键词 抑郁症 焦虑 度洛西汀 舍曲林 Depression Anxiety Duloxetine Sertraline
  • 相关文献

参考文献5

二级参考文献35

  • 1国效峰,赵靖平,陈晋东.度洛西汀:一种新型抗抑郁药[J].中国新药与临床杂志,2006,25(7):552-555. 被引量:88
  • 2Lott RS,Baker DE.Duloxetine:a new antidepressant[J].Adv Pharm,2003;1:228-241.
  • 3Melanie E,Hunziker,Brandon T,et al.Duloxetine hydrochloride:A new dual-acting medication for the treatment of major depressive disorder[J].Clin Ther,2005 ;27:1126-1143.
  • 4Detke M J,Lu Y,Goldstein D J,et al.Duloxetine,60 mg daily,for major depressive disorder:A randomized double-blind placebo controlled trial[J].J Clin Psychiatry,2002 ;63:308-315.
  • 5Detkea MJ,Lua YL.Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression[J].J Psychiatric Res,2002;36:383-390.
  • 6Goldstein D J,Mallincrodt C,Lu Y,et al.Duloxetine in the treatment of major depressive disorder:A double-blind clnical trial[J].J Clin Psychiat,2002 ;63:225-231.
  • 7Dunnera DL,Deborsh N.Is treatment-associated hypomania rare with duloxetine:Secondary analysis of controlled trials in non-bipolar depression[J].J Affect Disord,2005 ; 87:115-119.
  • 8Greist J,MeNamara RK,Mallinckrodt CH,et al.Incidence and duration of antidepressant-induced nausea:duloxetine compared with paroxetine and fluoxetine[J].Clin Ther,2004 ;26:1446-1455.
  • 9Brannan SK,Mallinckrodt CH,Detke M J,et al.Onset of action for duloxetine 60 mg once daily:double-blind,placebo-controlled studies[J].J Psyehiatr Res,2005;39:161-172.
  • 10Wernicke JF,Gahimer J,Yalcin I,et al.Safety and adverse event profile of duloxetine[J].Expert Opin Drug Saf,2005 ;4:987-993.

共引文献75

同被引文献38

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部